Showing results (361-370 of 427) with videos related to

Sort By:
Pageof 43
Hematological Oncology|April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinibFrancesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
American Journal of Hematology|March 15, 2016
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Hemasphere|September 4, 2023
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMAFabio Efficace, Wael Al Essa, Uwe Platzbecker, et al.
Hematological Oncology|February 22, 2021
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitorsRoberto Latagliata, Immacolata Attolico, Malgorzata Monika Trawinska, et al.
American Journal of Hematology|May 4, 2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinibFausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, et al.
American Journal of Hematology|October 15, 2013
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib eraMichele Malagola, Massimo Breccia, Cristina Skert, et al.
Annals of Hematology|October 4, 2017
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter seriesAlessandra Iurlo, Sara Galimberti, Elisabetta Abruzzese, et al.
Leukemia Research|December 9, 2015
Dasatinib first-line: Multicentric Italian experience outside clinical trialsMassimo Breccia, Fabio Stagno, Luigiana Luciano, et al.
Hematological Oncology|March 21, 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
British Journal of Haematology|February 9, 2022
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL studyElena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, et al.
Pageof 43